Takeda Pharmaceutical Company Limited (TAK) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TAK Revenue Growth
Revenue Breakdown (FY 2024)
TAK's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
TAK Revenue Analysis (2013–2024)
As of May 8, 2026, Takeda Pharmaceutical Company Limited (TAK) generated trailing twelve-month (TTM) revenue of $4.49 trillion, reflecting solid growth of +6.0% year-over-year. The most recent quarter (Q3 2025) recorded $1.21 trillion in revenue, up 9.0% sequentially.
Looking at the longer-term picture, TAK's 5-year compound annual growth rate (CAGR) stands at +6.8%, indicating steady revenue expansion. The company achieved its highest annual revenue of $4.58 trillion in 2024, representing a new all-time high.
Revenue diversification analysis shows TAK's business is primarily driven by Gastroenterology (30%), PDT Immunology (23%), and Rare Diseases (16%).
When compared to Healthcare sector peers including NVO (+8.1% YoY), AZN (+9.9% YoY), and SNY (+14.1% YoY), TAK has underperformed the peer group in terms of revenue growth. Compare TAK vs NVO →
TAK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TAKCurrent | $4.49T | +6.0% | +6.8% | 7.5% | |
 NVO | $309.1B | +8.1% | +19.5% | 41.3% | |
 AZN | $58.7B | +9.9% | +17.2% | 23.4% | |
 SNY | $46.7B | +14.1% | +4.6% | 13.6% | |
 NVS | $54.8B | +5.3% | +1.9% | 31.2% | |
 GSK | $32.7B | +5.4% | +6.0% | 25.5% |
TAK Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $4.58T | +7.5% | $3.00T | 65.5% | $342.59B | 7.5% |
| 2023 | $4.26T | +5.9% | $2.83T | 66.4% | $214.07B | 5.0% |
| 2022 | $4.03T | +12.8% | $2.78T | 69.1% | $490.50B | 12.2% |
| 2021 | $3.57T | +11.6% | $2.46T | 69.0% | $460.84B | 12.9% |
| 2020 | $3.20T | -2.8% | $2.20T | 68.9% | $509.27B | 15.9% |
| 2019 | $3.29T | +56.9% | $2.20T | 66.9% | $100.41B | 3.1% |
| 2018 | $2.10T | +18.5% | $1.44T | 68.5% | $204.97B | 9.8% |
| 2017 | $1.77T | +2.2% | $1.27T | 72.0% | $241.79B | 13.7% |
| 2016 | $1.73T | -4.2% | $1.17T | 67.7% | $155.87B | 9.0% |
| 2015 | $1.81T | +1.7% | $1.27T | 70.4% | $130.83B | 7.2% |
Full TAK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See TAK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TAK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TAK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTAK — Frequently Asked Questions
Quick answers to the most common questions about buying TAK stock.
Is TAK's revenue growth accelerating or slowing?
TAK maintains +6.0% revenue growth, in line with its 5-year CAGR of +6.8%. TTM revenue stands at $4.5T. Growth rate remains consistent with historical average.
What is TAK's long-term revenue growth rate?
Takeda Pharmaceutical Company Limited's 5-year revenue CAGR of +6.8% reflects the sustained expansion pattern. Current YoY growth of +6.0% is near this long-term average.
How is TAK's revenue distributed by segment?
TAK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.